Skip to main content Back to Top
Advertisement

4/11/2019

Dicyclomine Oral Presentations

Products Affected - Description

    • Dicyclomine hydrochloride capsule, Hikma, 10 mg, bottle, 100 count, NDC 00143-3126-01
    • Dicyclomine hydrochloride capsule, Hikma, 10 mg, bottle, 1000 count, NDC 00143-3126-10
    • Dicyclomine hydrochloride tablet, Hikma, 20 mg, bottle, 100 count, NDC 00143-1227-01
    • Dicyclomine hydrochloride tablet, Hikma, 20 mg, bottle, 1000 count, NDC 00143-1227-10
    • Dicyclomine hydrochloride capsule, Lannett, 10 mg, bottle, 100 count, NDC 00527-0586-01
    • Dicyclomine hydrochloride capsule, Lannett, 10 mg, bottle, 1000 count, NDC 00527-0586-10
    • Dicyclomine hydrochloride tablet, Lannett, 20 mg, bottle, 100 count, NDC 00527-1282-01
    • Dicyclomine hydrochloride tablet, Lannett, 20 mg, bottle, 1000 count, NDC 00527-1282-10
    • Dicyclomine hydrochloride capsule, Mylan, 10 mg, bottle, 100 count, NDC 00378-1610-01
    • Dicyclomine hydrochloride capsule, Mylan, 10 mg, bottle, 500 count, NDC 00378-1610-05
    • Dicyclomine hydrochloride tablet, Mylan, 20 mg, bottle, 100 count, NDC 00378-1620-01
    • Dicyclomine hydrochloride tablet, Mylan, 20 mg, bottle, 500 count, NDC 00378-1620-05
    • Dicyclomine hydrochloride capsule, Mylan Institutional, 10 mg, unit-dose blister pack, 100 count, NDC 51079-0118-20
    • Dicyclomine hydrochloride tablet, Mylan Institutional, 20 mg, unit-dose blister pack, 100 count, NDC 51079-0119-20
    • Dicyclomine hydrochloride tablet, Teva, 20 mg, bottle, 1000 count, NDC 00591-0795-10

Reason for the Shortage

    • Hikma did not provide a reason for the shortage.
    • Lannett did not provide a reason for the shortage.
    • Mylan did not provide a reason for the shortage.
    • Par Pharmaceuticals has dicyclomine oral solution available.
    • Teva did not provide a reason for the shortage.

Available Products

    • Dicyclomine hydrochloride solution, Par Pharmaceuticals, 10 mg/5 mL, 473 mL bottle, NDC 00603-1161-58
    • Dicyclomine hydrochloride capsule, Teva, 10 mg, bottle, 100 count, NDC 00591-0794-01
    • Dicyclomine hydrochloride capsule, Teva, 10 mg, bottle, 1000 count, NDC 00591-0794-10
    • Dicyclomine hydrochloride tablet, Teva, 20 mg, bottle, 100 count, NDC 00591-0795-01

Estimated Resupply Dates

    • Hikma has 10 mg capsules in 100 and 1,000 count bottles and 20 mg tablets in 100 and 1,000 count bottles available on allocation.
    • Lannett has 10 mg capsules in 100 and 1,000 count bottles on back order and the company estimates a release date of mid-May 2019. The 20 mg tablets in 100 count bottles are on back order and the company cannot estimate a release date. The 20 mg tablets in 1,000 count bottles are on back order with an estimated release date of early-May 2019.
    • Mylan has 10 mg capsules in 100 and 500 count bottles on back order and the company estimates a release date of mid-June 2019 for the 100 count bottles and mid-August for the 500 count bottles. The 20 mg tablets in 100 and 500 count bottles are on back order and the company estimates a release date of mid-June 2019.
    • Mylan Institutional has 10 mg capsules and 20 mg tablets on back order and the company estimates a release date of early-September 2019 for the 10 mg capsules and late-July 2019 for the 20 mg tablets.
    • Teva has 20 mg tablets in 1,000 count bottles on back order and the company estimates a release date of early-May 2019.

Updated

Updated April 11, 2019 by Anthony Trovato, PharmD, BCPS. Created January 22, 2019 by Stephen Andrews, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins